INNODIA receives regulatory approval to start MELD-ATG
11. September 2020
BREAKING: INNODIA received approval from the regulatory authorities to start MELD-ATG, a study for newly diagnosed type one diabetes patients between 5 and 25. INNODIA wants to identify the minimum effective dose of ATG (Anti-Thymocyte Globulin), a drug provided by our partner Sanofi. The aim is to slow down the onset of the disease and to protect and strengthen the insulin producing beta cells in the pancreas. Moving forward towards better treatment!